Several Brokerage Firms Initiate Coverage on Talecris Biotherapeutics (TLCR)
TLCR Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
J.P. Morgan initiates coverage on Talecris Biotherapeutics (Nasdaq: TLCR) with an Overweight.
Goldman initiates coverage on TLCR with a Neutral. Price target $24
Morgan Stanley initiates TLCR with an Overweight. PT $24
Citi also initiates coverage on TLCR with a Buy rating. PT $28
To see more analyst ratings on TLCR Click Here.
Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide.
Goldman initiates coverage on TLCR with a Neutral. Price target $24
Morgan Stanley initiates TLCR with an Overweight. PT $24
Citi also initiates coverage on TLCR with a Buy rating. PT $28
To see more analyst ratings on TLCR Click Here.
Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- UPDATE: Patriot Coal (PCX) Continues to Work with Lenders to Strengthen Financing, Hired Blackstone
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
Create E-mail Alert Related Categories
New CoverageRelated Entities
JPMorgan, Citi, Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
